Twin Peaks Wealth Advisors’s Amicus Therapeutics FOLD Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$636	Buy	+44	New	+$631	﹤0.01%	1992

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Twin Peaks Wealth Advisors's FOLD Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 44 shares worth $636. The stake represents ﹤0.01% of the portfolio and ranks #1992 among its holdings.

298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Twin Peaks Wealth Advisors held 44 shares of Amicus Therapeutics worth $636 as of Q1 2026.
Amicus Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1992 holding.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.